Vaccines developer Icosavax procures $52 mln Series A
Seattle-based vaccines developer Icosavax has secured $52 million in Series A funding. Qiming Venture Partners USA led the round with participation from Adams Street Partners, Sanofi Ventures and NanoDimension.
3 October 2019•1 min read
